Adverse outcomes for chronic myeloid leukemia patients with splenomegaly and low in vivo kinase inhibition on imatinib

Variability in the molecular response to frontline tyrosine kinase inhibitor (TKI) therapy in chronic myeloid leukemia may be partially driven by differences in the level of kinase inhibition induced. We measured in vivo BCR::ABL1 kinase inhibition (IVKI) in circulating mononuclear cells after 7 day...

Descripción completa

Detalles Bibliográficos
Autores principales: Kok, Chung H., Saunders, Verity A., Dang, Phuong, Shanmuganathan, Naranie, White, Deborah, Branford, Susan, Yeung, David, Hughes, Timothy P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10495334/
https://www.ncbi.nlm.nih.gov/pubmed/37696829
http://dx.doi.org/10.1038/s41408-023-00917-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10495334/
https://www.ncbi.nlm.nih.gov/pubmed/37696829
http://dx.doi.org/10.1038/s41408-023-00917-4

Ejemplares similares